Skip to main content
NACFC 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestream
Livestream
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session

APPTT
Thematic Poster Session

TPS04--Imaging & Clinical Outcome Measures

Friday, November 3, 2023
9:30 AM - 11:00 AM MST
Location:Theater C (Exhibit & Poster Hall)

The session consists of two main parts: (1) poster viewing followed by a (2) moderated discussion. It is designed to engage the authors and the audience in a discussion that ties together ideas from multiple posters in the session.

Clinical trials of adjunctive and disease-modifying therapies in the highly effective modulator era require innovative endpoints. This session will highlight and discuss a number of novel imaging and clinical outcome measures, their potential role in future CF studies, and their applicability to disease monitoring in clinical practice. Attendees will gain a greater insight into the design, derivation and validation of the imaging modalities and clinical scoring systems presented and the patient populations they apply to.

Seating is limited to 65 seats.

Learning Objectives:

  • Summarize the emerging clinical outcome measures and imaging platforms for clinical care and clinical trials in CF.
  • Appraise the design, derivation and validation of clinical prognostic scores and outcome measures.
  • Compare the applicability of the imaging modalities and clinical outcome measures described across different CF patient populations.

Presentations:

  • 9:30 AM - 11:00 AM MST
    TPS04.1- Elexacaftor-Tezacaftor-Ivacaftor and spirometry-controlled chest CT scores in people with CF aged 6-11 years

    Speaker: Karen Lester

  • 9:30 AM - 11:00 AM MST
    TPS04.2- Hyperpolarized 129Xe pulmonary magnetic resonance imaging and multiple breath washout to measure response to elexacaftor/tezacaftor/ivacaftor therapy in children

    Speaker: Vanessa M. Diamond, BSc (she/her/hers) – University of British Columbia

  • 9:30 AM - 11:00 AM MST
    TPS04.3- Elexacaftor/Tezacaftor/Ivacaftor Improves Bronchial Artery Dilatation Detected by Magnetic Resonance Imaging in Patients with Cystic Fibrosis

    Speaker: Lena Wucherpfennig (she/her/hers) – University Hospital Heidelberg

  • 9:30 AM - 11:00 AM MST
    TPS04.4- Interim Results of Test Reliability of 19F MRI in Mild CF Lung Disease

    Speaker: Jennifer L. Goralski, MD – The University of North Carolina at Chapel Hill

  • 9:30 AM - 11:00 AM MST
    TPS04.5- Lung T1-MRI and Multi-Breath Washout detect longitudinal lung changes in children beginning elexacaftor/tezacaftor/ivacaftor (ETI) therapy.

    Speaker: Samya Z. Nasr, MD (she/her/hers) – University of Michigan

  • 9:30 AM - 11:00 AM MST
    TPS04.6- Longitudinal magnetic resonance imaging of morphological and perfusion abnormalities in patients with cystic fibrosis from infancy to end of adolescence

    Speaker: Mark Wielpütz, MOW – Heidelberg University Hospital

  • 9:30 AM - 11:00 AM MST
    TPS04.7- Comprehension of early CF lung disease or how to TRACK-CF

    Speaker: Eva Steinke, MD (she/her/hers) – Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Germany

  • 9:30 AM - 11:00 AM MST
    TPS04.8- Oxygen Enhanced(OE)-MRI and Multiple breath washout with Short extension(MBWShX) are highly sensitive to Elexacaftor-Tezacaftor-Ivacaftor(ETI) initiation in a group with preserved pulmonary function

    Speaker: Christopher Short, MRes – Imperial College London

  • 9:30 AM - 11:00 AM MST
    TPS04.9- The Lung Clearance Index to Inform Clinical Decision-Making in Early CF Lung Disease: Findings from a Prospective Study

    Speaker: Lucy M. Perrem, MD MSc PhD (she/her/hers) – Children's Health Ireland

  • 9:30 AM - 11:00 AM MST
    TPS04.10- Increasing the value of clinic visits for patients, families, and staff through annual lab pre-visit planning

    Speaker: Shaili Rajput, MD, MPH (she/her/hers) – Kaiser Northwest Permanente